$FENC

B.Riley initiates Fennec Pharmaceuticals stock with Buy rating, $16 target

B.Riley has initiated coverage on Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy rating and a $16 price target, citing significant undervaluation of its PEDMARK commercial potential. The firm highlights PEDMARK as the only FDA-approved therapy for cisplatin-induced hearing loss risk, with no approved competitors. Recent positive developments include record sales, an operating cash flow-positive quarter, and the company's full repayment of outstanding debt.

Original reporting
Investing.com · Investing.com
Published Feb 12, 2026, 8:21 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Feb 12, 2026, 9:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
B.Riley initiates Fennec Pharmaceuticals stock with Buy rating, $16 target — source image
Decision brief

The 30-second read

$FENCBullishHigh
01

Why it matters

The analyst coverage and recent financial milestones could catalyze stock appreciation, especially if sales continue to grow and debt is managed effectively.

02

Market read

The news is highly relevant for biotech investors and traders focusing on innovative therapies with strong regulatory backing.

03

What to watch

Potential regulatory hurdles or competitive developments could impact Fennec's growth trajectory.

Timing: Immediate to short-term (next 1-3 months)

Background

Fennec Pharmaceuticals has recently received positive attention due to its FDA-approved drug PEDMARK, addressing a significant unmet medical need with no direct competitors.

Company-level read

Ticker impact

$FENCBullishHigh confidence
Context

High relevance due to recent analyst coverage and positive developments.

Expected impact

Moderate to significant increase in stock price over the next 1-3 months.

Evidence & confidence

The combination of analyst endorsement, positive sales trends, and debt repayment indicates solid fundamentals and growth prospects.

Market effects

Positive outlook for life sciences sector, especially biotech firms with FDA-approved therapies.

Potential uplift in US biotech stocks due to increased investor confidence.

Limited; primarily US-focused developments.

Counterpoint

The analyst rating may be overly optimistic; actual sales growth and market acceptance could be slower than anticipated.

Key entities

  • Fennec Pharmaceuticals

    Biotech firm specializing in therapies for hearing loss.

  • B.Riley

    Investment firm initiating coverage with a positive outlook.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.

$NOCMed

WP: Pentagon asks defense companies to urgently ramp up weapons production

The Pentagon, via Deputy Secretary Steve Feinberg, urged U.S. defense firms to accelerate weapons output, especially ammunition, and asked executives to submit production and delivery plans within 21 days, according to The Washington Post. CSIS data cited Patriot and THAAD stockpiles falling sharply. The article notes talks with Northrop Grumman and Lockheed Martin and a Lockheed contract up to $58.6B to triple PAC-3 output by 2030.